Check Cap Ltd (CHEK) Given the average recommendation of "Strong Buy" from Brokerages



Check Cap Ltd (NASDAQ: CHEK) received an average mediation score of 1.00 (Strong Buy) from the two analysts who provide coverage for the company, reports from Zacks Investment Research. Two analysts have assessed the shares with a strong buy-rating.

Brokers have set a 12-month consensus target of $ 8.38 for the company and predict that the company will publish ($ 0.53) EPS for the current quarter, according to Zacks. Zacks also gave Check Cap an industry ranking of 120 out of 255 based on the ratings given to related companies.

A number of equity analysts have issued reports on the shares. HC Wainwright reconfirmed a "buy" rating on Wednesday, May 23, and set a target price of $ 14.00 for Check Cap shares in a research report. Zacks Investment Research increased the share of Check Cap from a & # 39; hold & # 39; credit to a & # 39; buy & # 39; credit rating and set a price target of $ 5.00 for the company in a research report on Wednesday, May 9.

Check Cap opened on Friday at $ 3.22, according to Marketbeat. Check Cap has a 12 month low of $ 3.12 and a 12 month high of $ 24.00.

Check Cap (NASDAQ: CHEK) has last published the quarterly results on Thursday, August 9th. The medical research firm reported ($ 0.70) Earnings per Share (EPS) for the quarter, with consensus analysts' estimates above ($ 0.82) dropping by $ 0.12. analysts predict that Check Cap will book -2.6 profit per share for the current fiscal year.

About Check Cap

Check-Cap Ltd., a clinical stage of medical diagnostics, is engaged in the development of a capsule-based system that uses low-dose x-rays for screening of the colon for polyps, masses & colorectal cancers in Israel to detect. The C-Scan system consists of C-Scan Cap, an X-ray scan capsule, designed to measure, collect and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for control of the capsule, tracking and data recording; and C-Scan View, a personal computer-based software package designed to retrieve and process clinical data from the C-Scan track, and to reconstruct and produce 3D visualization of the inner surface of the colon .

Recommended story: stock symbol

Receive a free copy of Zacks research report on Check Cap (CHEK)

Visit Zacks.com for more information about research offers from Zacks Investment Research



Receive news and ratings for Check Cap Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst reviews for Check Cap and related companies with the FREE daily email newsletter from MarketBeat.com.


Source link

Leave a Reply